Evaluating the atittudes of Australian psychologists, psychiatrists and mental health researchers towards 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for the treatment of PTSD: A double-blind, randomised controlled trial
This double-blind, randomised controlled trial (n=200) aims to evaluate the attitudes of Australian psychologists, psychiatrists, and mental health researchers towards MDMA-assisted psychotherapy for the treatment of PTSD.
Details
Online, parallel-group randomized vignette study recruiting Australian psychologists, psychiatrists and mental health researchers who read a single vignette describing a hypothetical Phase 3 trial of either MDMA-assisted psychotherapy or a fabricated drug (JB-4801) plus psychotherapy.
Participants complete a ~10-minute survey (one timepoint between February and November 2020) with outcomes including subjective safety concern (10-point Likert) and predicted efficacy (10-point Likert). No direct contact or actual drug administration occurs.